Skip to content

Author

T. Passeron

We have 1 of 571 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Vitiligo Biomarker CXCL10 Correlates With Clinical Response to Ruxolitinib Cream in the Phase 2 Randomized TRuE-V Mechanism-of-Action Study.

Data confirm a role for the IFN-γ-CXCL10 axis in vitiligo pathogenesis and suggest that reductions in CXCL10 expression correlate with clinical repigmentation with ruxolitinib cream.

T. Passeron, M. Lebwohl, C. Lynde et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.